Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucagon therapy for beta-blocker overdose.

C D Peterson, J S Leeder, S Sterner

    Drug Intelligence & Clinical Pharmacy
    |May 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Peripherally mediated opioid combination therapy in mouse and pig.

    The journal of pain·2024
    Same author

    Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.

    Pediatric obesity·2018
    Same author

    Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

    Clinical pharmacology and therapeutics·2017
    Same author

    Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics.

    Clinical pharmacology and therapeutics·2016
    Same author

    Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro.

    Clinical and translational science·2016
    Same author

    Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.

    Clinical pharmacology and therapeutics·2015
    Same journal

    Profile of prescription medication in a pediatric population.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    SI units in drug therapeutics.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Physicians' review of significant interventions by clinical pharmacists in inpatient care.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Possible interaction of ranitidine with phenytoin.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Famotidine-associated mental confusion in elderly patients.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy.

    Drug intelligence & clinical pharmacy·1988
    See all related articles

    Glucagon therapy effectively reverses cardiovascular depression from severe beta-blocker overdose. This treatment offers a viable alternative when standard therapies fail, despite potential cost and availability issues.

    Area of Science:

    • Cardiology
    • Toxicology
    • Pharmacology

    Background:

    • Beta-blocker overdose can cause severe cardiovascular complications like hypotension and bradycardia.
    • Standard treatments such as atropine and isoproterenol are often inconsistent in managing these effects.

    Observation:

    • Two cases of severe beta-blocker overdose successfully treated with glucagon therapy are presented.
    • Glucagon demonstrated efficacy in reversing cardiovascular depression unresponsive to other interventions.

    Findings:

    • Glucagon increases heart rate and myocardial contractility, improving atrioventricular conduction.
    • Its mechanism of action appears to bypass beta-adrenergic receptors, making it effective even with profound beta-blockade.
    • Recommended dosage: 50 mcg/kg IV loading dose followed by 1-15 mg/h infusion, titrated to response.

    Related Experiment Videos

    Implications:

    • Glucagon is a potential alternative therapy for severe beta-blocker intoxications.
    • Monitoring for side effects including nausea, vomiting, hypokalemia, and hyperglycemia is crucial.
    • High cost and limited availability may impact widespread clinical adoption.